期刊文献+

多靶点受体酪氨酸激酶抑制剂ABT-869的有效合成方法 被引量:1

Synthesis of a Multiple Target Receptor Tyrosine Kinase Inhibitors ABT-869
原文传递
导出
摘要 ABT-869是结构新型有效的多靶点受体酪氨酸激酶抑制剂,目前正处在III期临床研究阶段.从商业廉价易得的间氟苯胺出发,以较低的成本经过7步反应以42.3%的总收率实现了多靶点受体酪氨酸激酶抑制剂ABT-869全合成.该工艺在关键步骤Suzuki偶联反应中使用了超声波反应器,极大地缩短反应时间,提高了收率,并且该工艺各步反应中间体不用纯化直接投入下步反应,最终产物只需结晶纯化即可达到大于99%的纯度,无需传统的柱层析分离,更适合于工业生产. An efficient and convenient protocol for the synthesis of ABT-869, which is a multiple target receptor tyrosine kinase inhibitors with novel structure and high inhibitory activity, was developed in seven steps from cheap and commercially available of 3-fluoroaniline. The target molecular was obtained in 42.3% overall yield without any traditional purification(column chromatography or crystallization). Ultrasonic reaction technology was introduced in the Suzuki coupling reaction which is the key step of the preparation of ABT-869. The synthetic process was more suitable for industrialized production due to the advantages of available starting material, simplicity and cheapness, well yield and purity(HPLC99.0%).
出处 《有机化学》 SCIE CAS CSCD 北大核心 2014年第6期1196-1200,共5页 Chinese Journal of Organic Chemistry
基金 河南省教育厅科学技术研究重点(Nos.14A150052 12A150026) 郑州市科技攻关计划(No.121PPTGG509-2)资助项目~~
关键词 受体酪氨酸激酶抑制剂 ABT-869 合成 receptor tyrosine kinase inhibitors ABT-869 synthesis
  • 相关文献

参考文献14

  • 1徐芳媛,邢爱敏.抗肿瘤药Linifanib[J].药学进展,2010,34(7):329-331. 被引量:3
  • 2Hernandez, D. J. E.; Zape, J. P.; Landaw, E. M.; Tan, X.; Presnell, A.; Griffith, D.; Heinrich, M. C.; Glaser, K. B.; Sakamoto, K. M. Mol. Cancer Ther. 21)11, 10(6), 949. 被引量:1
  • 3(a) Guo, J.; Patrick, A. M.; J, Owen, M. C.; Dai, Y. J.; Lori, J. P.; Michael, R. M.; Steven, K. D.; Keith, B. G. Mol. Cancer Ther. 2006, 5(4), 1007. 被引量:1
  • 4(b) Fang, J.; Daniel, ld. A.; Yanping, L.; Paul, T.; Ke, Z.; Steven, K. D.; Gerard, B. F.; Richard, L.; Evetyn, M. M. J. Pharmacol. Exp. Ther. 2011, 338(1), 134. 被引量:1
  • 5(a) Wang, E. S.; Yee, K.; Koh, L. P.; Hogge, D.; Enschede, S.; Carlson, D. M.; Dudley. M.; Glaser, K.; Mckeegan, E.; Albert, D. H.; Li, X.; Pradhan, R.; Stock, W. Leuk. Lymphoma 2012, 53(8), 1543. 被引量:1
  • 6(b) Mudd, S. R.; Voorbach, M. J.; Reuter, D. R.; Tapang, P.; Hick- son, J. A., Refici, B. M.; Fox, G. B.; Albert, D. H.; Luo, Y.; Day, M. Cancer Chemother. Pharmacol. :012, 69(6), 1669. 被引量:1
  • 7(c) Toh, H. C.; Chen, P. J.; Carr, B. I.; Knox, J. J.; Gill, S.; Ansell, P.; Mckeegan, E. M.; Dowell, B.; Pedersen, M.; Qin, Q.; Qian, J.; Scappaticci, F. A.; Ricker, J. L.; Carlson, D. M.; Yong, W. P. Can- cer 2013, 119(2), 380. 被引量:1
  • 8Dai, Y. J.; Hartandi, K.; Ji, Z. Q. J. Med. Chem. 2007, 50(7), 1584. 被引量:1
  • 9Kruger, A. W.; Rozema, M. J.; Chu-Kung, A. Org. Process Res. Dev. 2009, 13(6), 1419. 被引量:1
  • 10刘海龙,朱五福,果秋婷,王建强,王晓,宫平.抗肿瘤药物linifanib的合成[J].中国药物化学杂志,2012,22(1):26-28. 被引量:4

二级参考文献17

  • 1Filler R.The asymmetric synthesis of α-amino acids remains an important challenge for organic chemists [J].Chemtech, 1974, 752. 被引量:1
  • 2Kumadaki I..Synthesis of enantiomerically pure phenylalanine analogues [J].J Synth Org Chem Jpn. ,1984, 42: 786. 被引量:1
  • 3Yaskioka H, Takayama C, Matsuo N.α-Amino acid synthesis [J].J Synth Org Chem Jpn ,1984, 42:809. 被引量:1
  • 4J Carbon Ydr. res 4(Special fluorocarbhydrate issue) [J]. Chemtech ,1995,25:126. 被引量:1
  • 5Penglist A A E. Systhesis of 3-(2-furoyl)-L-alanine [J].Adv Carbohydr Chem Biochem, 1981, 38: 195. 被引量:1
  • 6Foster A B, Westwood J H.For studies on the biosynthesis to isolation and biological activity [J].Pure and Applied Chem, 1973, 35:147. 被引量:1
  • 7Kent P W. Total synthesis of L-β-(5-hydroxy-2-pyridyl)alanine [J].Chem Ind, 1969,1128. 被引量:1
  • 8陶克美.[D].上海:华东师范大学,2001年. 被引量:1
  • 9G C Finger,M J.Gortatowski,R.H.Shiley.A concise synthesis of the differentiating2-iodo-5-methoxypyridine [J]. J Am Chem Soc, 1959,81:94~101. 被引量:1
  • 10James English,Jr,James F Mead,Carl Niemann. Synthesis of L-azatyrosine [J].J Am Chem Soc., 1940,62:350~354 被引量:1

共引文献5

同被引文献24

  • 1刘亚方,李洪玉,李金岭,姜申德.瑞格拉非尼(Regorafenib)的合成[J].精细化工中间体,2012,42(6):31-34. 被引量:7
  • 2Chiu Y L,Carlson D M,Pradhan R S,et al.Exposure-response(safety)analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma[J].Clin Ther,2013,35(11):1 770-1 777. 被引量:1
  • 3FDA.FDA approves regorafenib(Stivarga)for GIST[J].Oncol(Williston Park),2013,27(3):164. 被引量:1
  • 4Wu G G,Chen F X,La France D,et al.A novel iodide-catalyzed reduction of nitroarenes and aryl ketones with H3PO2or H3PO3:Its application to the synthesis of a potential anticancer agent[J].Organic letters,2011,13(19):5 220-5 223. 被引量:1
  • 5Gang L,Brian T C,Mark W,et al.Holladay discovery of AC710,a globally selective inhibitor of platelet-derived growth factor receptor-family kinases[J].Med Chem Lett,2012,3(12):997-1 002. 被引量:1
  • 6Pam A,Yi F,Yuan M,et al.Discovery of GNF-5837,a selective TRK inhibitor with efficacy in rodent cancer tumor models[J].Med Chem Lett,2012,3(2):140-145. 被引量:1
  • 7Li W W,Wang X Y,Zheng R L,et al.Discovery of the novel potent and selective FLT3 inhibitor1-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia(AML)activities in vitro and in vivo[J].Med Chem,2012,55(8):3 852-3 866. 被引量:1
  • 8Yang L L,Li G B,Ma S,et al.Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and Evaluation of its activity against acute myeloid leukemia in vitro and in vivo[J].Med Chem,2013,56(4):1 641-1 655. 被引量:1
  • 9Zhang Q W,Diao Y Y,Wang F,et al.Design and discovery of 4-anilinoquinazoline ureas as multikinas inhibitors targeting BRAF,VEGFR-2 and EGFR[J].Med Chem Commun,2013,4:979-986. 被引量:1
  • 10Wang C,Dong J Y,Zhang Y M,et al.Design,synthesis and biological evaluation of biphenyl urea derivatives as novel VEGFR-2 inhibitors[J].Med Chem Commun,2013,4:1 434-1436. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部